Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
68 Results Found
AHA 340B Advocacy Alliance Bulletin - January 12, 2026
Several health care groups, including the AHA, today told the Centers for Medicare & Medicaid Services it is wrong to tell hospitals and health systems they “are to” complete the agency’s Outpatient Prospective Payment System Drug Acquisition Cost Survey and urged CMS to correct an FAQ issued on the issue.
AHA 340B Advocacy Alliance Bulletin - January 7, 2026
The United States Court of Appeals for the First Circuit today denied the government’s motion for a stay in a lawsuit filed by the AHA, the Maine Hospital Association, and four safety-net health systems challenging the 340B Rebate Model Pilot Program.
AHA 340B Advocacy Alliance
A Bloomberg article published today (linked here and text below) discusses how the Department of Health and Human Services plans to “survey safety-net hospitals on the amount they pay for prescription drugs, following up on an effort to reduce the hospitals’ Medicare drug reimbursement during the president’s first term.”
340B Advocacy Alliance Bulletin - July 29, 2025
Register for Aug. 1 AHA Site-neutral Advocacy Alliance Call.
AHA 340B Advocacy Alliance Bulletin - October 30, 2025
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model Pilot Program with a start date of Jan. 1, 2026.
AHA 340B Advocacy Alliance Newsletter
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug manufacturers to effectuate the 340B ceiling price on select drugs to all 340B covered entities.
AHA 340B Advocacy Alliance Bulletin - September 24, 2025
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges against the state’s law protecting 340B pricing for contract pharmacy arrangements.